Finnexia is indicated for the treatment of Finno-Ugric language deficiency. The medication is specially formulated to activate specific neuroreceptors involved with the acquisition of Finno-Ugric languages - the Finnish language in particular. Finnexia provides a form of cognitive and speech enhancement that allows one to learn the Finnish language more easily and quickly.
Finnexia works primarily by activating areas of the frontal and prefrontal cortex of the brain that are responsible for language and speech activity. It contains a unique dual-action mechanism that enhances Finnish language acquisition, while subduing the anxiety often associated with learning a foreign language. Finnexia stimulates the pathways that aid in cognitive processes, memory, and speech comprehension. The primary agent in Finnexia is an Alpha-7 nicotine acetylcholine receptor agonist. This type of agonist has been found to enhance cognitive abilities by modulating post-synaptic Alpha-7 receptors in the prefrontal cortex of the brain. Stimulation of the receptor increases calcium permeability and thereby the firing rate of stimulated neurons.
Because Finnish is one of the most difficult languages to learn, for most people, a significant numbers of hours are required for learning. The effectiveness of Finnexia was studied in a phase III double-blind, randomized clinical trial with 600 patients. The trial evaluated the average reduction in hours that were required for mastery of the language in patients treated with Finnexia, versus those that were treated with placebo. Finnexia was proven to reduce the number of necessary classroom learning hours from 200 to 25, an 800% reduction of effort. After only 25 hours of study while using Finnexia, patients were able to demonstrate the same level of Finnish language competency as those who had studied 200 hours.
Watch the Finnexia animation, and learn how the medication works in the brain to enhance cognitive and speech functions. Special medical terms are explained further in the Glossary section of this site.